Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice
View More
Community Practice Connections™: Navigating a New Era of Food Allergy Management
View More
Community Oncology Connections™: Contextualizing Novel Immunotherapy for Advanced Melanoma – How Do TIL Therapies Fit into Practice? | Arizona
View More
Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | Nevada
View More
Eye Care Symposia in Los Angeles
April 25-26, 2025
Register Now!
Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | Missouri
View More
Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | New Mexico
View More
Upstate New York Hematology & Hematologic Oncology Conference: A Review of the 66th ASH Annual Meeting
April 26-27, 2025
Register Now!
Hepatitis D Patients Maintain Undetectable Virus Nearly 2 Years After Bulevirtide Therapy
May 10th 2025Anu Osinusi, MD provides insights on the findings of Gilead’s investigational therapy from its phase 3 MYR301 study, which are being reported at the ongoing European Association for the Study of the Liver (EASL) Congress 2025.
US Businesses Are Here to Help the Trump Administration Keep its Pledge to End HIV
May 9th 2025A coalition of over 100 US companies is supporting the federal initiative to end the HIV epidemic by 2030, but legal and funding threats now jeopardize this progress and the significant health and economic benefits it promises.
Has Measles Become a Binary Choice Between Trying to Treat the Disease Vs Prevention?
May 8th 2025Paul Offit, MD, offers insights on the state of measles today where some families are opting to believe treatment is a better option than vaccination. He also discusses the potential toxicity of vitamin A treatment, as well as the limitations of supportive treatment for the disease.
Addressing Gram-Negative Infections With Further Insights From Cefiderocol's PROVE Study
May 5th 2025Sean Nguyen PharmD, BCIDP, medical director Shionogi, delves into the European cohort portion of the study and offers further information from the trial and some of its bigger clinical ramifications.